Ecansya (previously Capecitabine Krka) (capecitabine)
- Region
- 🇪🇺 EU
- Active substance
- capecitabine
- Company
- KRKA tovarna zdravil d.d. Novo mesto
- Status
- Authorised
- Therapeutic area
- Colonic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Stomach Neoplasms
- EU approval
- Fri 20 Apr 2012
- Designations
- Generic
- Application
- EMEA/H/C/002605
- ATC
- L01BC06
- Official record
- www.ema.europa.eu
Indication
Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer. Ecansya is indicated for the treatment of metastatic colorectal cancer. Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen. Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Capecitabine Teva Authorised · Teva Pharma B.V.
- 🇪🇺 Capecitabine Medac Authorised · medac Gesellschaft für klinische Spezialpräparate mbH
- 🇪🇺 Capecitabine Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Xeloda Authorised · CHEPLAPHARM Arzneimittel GmbH
- 🇪🇺 Capecitabine SUN Withdrawn · Sun Pharmaceutical Industries Europe B.V.
Follow Ecansya (previously Capecitabine Krka)
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.